Once Daily Tacrolimus Formulation: Monitoring of Plasma Levels, Graft Function, and Cardiovascular Risk Factors

Transplantation Proceedings

Volumn 42, Issue 4, 2010, Pages 1317-1319

  Mecule A ^a   Poli, L ^b   Nofroni, I ^c   Bachetoni, A ^b   Tinti, F ^a   Umbro, I ^a   Barile, M ^a   Berloco, P B ^b   Mitterhofer, A P ^a  

^a DAI Nefro Urologico   (Italy)

^b Specialità Chirurgiche e Trapianti d'Organo Paride Stefanini   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MONITORING; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; CADAVER; CARDIOVASCULAR DISEASES; CHOLESTEROL; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIVING DONORS; MALE; MIDDLE AGED; RISK FACTORS; TACROLIMUS; TISSUE DONORS; TRIGLYCERIDES;

EID: 77952594383     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.03.123     Document Type: Article

References (9)

1. Alloway R., Steinberg S., Khalil K., et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 83 (2007) 1648
2. Alloway R., Steinberg S., Khalil K., et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 37 (2005) 867
3. Roy First M., and Fitzsimmons W.E. Modified release tacrolimus. Yonsei Med J 45 (2004) 1127
4. Gaston R.S., Hudson S.L., Ward M., et al. Late renal allograft loss: non-compliance masquerading as chronic rejecton. Transplant Proc 31 (1999) S21
5. Lindholm A., Albrechtsen A., Frodin L., et al. Ischemic heart disease. Major cause of death and graft loss after renal transplantation in Scandinavia. Tansplantation 60 (1995) 451
6. Hopkins P.A., and Williams R.R. A survey of 246 suggested coronary risk factors. Atherosclerosis 40 (1981) 1
7. Ishibashi M., Yoshida K., Ozono S., et al. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding Cmax. Transplant Proc 33 (2001) 559
8. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461
9. TACR Flex Dimension (package insert): Dade Behring; 2006